Benzodiazepine-diones, a process for their production and their use as medicaments

Claim 2

A compound which is a 6,7-Dihydro-5H, 13H-quinazolin [3,2-a][1,4]benzodiazepine-5,13-dione of the formula (I) or its pharmacologically acceptable acid-addition salts: ##STR44## in which R 1 and R 5 are the same or different and each represents 0, 1, 2, 3 or 4 substituents which are the same or different and each of which is alkyl, hydroxyl, acyloxy, alkoxy, nitro, amino, alkylamino, dialkylamino, acylamino, acylalkylamino, alkoxycarbonylamino, halogen, trifluoromethyl, cyano, carboxyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, aminosulphonyl, alkylaminosulphonyl, dialkylaminosulphonyl, alkylaminocarbonylamino or dialkylaminocarbonylamino, each of said alkyl, alkoxy and acyl radicals having 1 to 4 carbon atoms R 2 is hydrogen, alkyl having from 1 to 6 carbon atoms and optionally substituted by phenyl, pyridyl, halogen, alkoxy or dialkylamino, each of the alkyl and alkoxy moieties containing from 1 to 4 carbon atoms, or an alkoxycarbonyl group having from 1 to 4 carbon atoms in the alkoxy moiety and R 3 and R 4 are the same or different and each is hydrogen, alkyl having from 1 to 4 carbon atoms or phenyl.

Claim 3

A compound according to claim 1 in which R 1 and R 5 are the same or different and each represents 0, 1 or 2 substituents which are the same of different and each of which is halogen, nitro, cyano, trifluoromethyl, amino, alkyl having from 1 to 4 carbon atoms or alkoxy having from 1 to 4 carbon atoms, R 2 is hydrogen, alkyl having from 1 to 6 carbon atoms and optionally substituted by phenyl, pyridyl, halogen, alkoxy or dialkylamino, each of the alkyl and alkoxy moieties containing from 1 to 4 carbon atoms, or an alkoxycarbonyl group having from 1 to 4 carbon atoms in the alkoxy moiety and R 3 and R 4 are the same or different and each is hydrogen, alkyl having from 1 to 4 carbon atoms or phenyl.

Claim 4

A compound according to claim 1 in which R 3 and R 4 are hydrogen.

Claim 5

A compound according to claim 1 in which R 1 and R 5 are the same or different and each is hydrogen or halogen, R 2 is hydrogen, alkyl having from 1 to 6 carbon atoms or an alkoxy carbonyl group having from 1 to 4 carbon atoms in the alkoxy moiety and R 3 and R 4 are hydrogen.

Claim 6

The compound according to claim 1 which is 6,7-dihydro-5H,13H-quinazolino[3,2-a][1,4]benzodiazepine-5,13-dione.

Claim 7

The compound according to claim 1 which is 2-chloro-6,7-dihydro-5H-13H-quinazolino 3,2-a 1,4 benzodiazepine-5,13-dione.

Claim 8

The compound according to claim 1 which is 6-ethoxycarbonyl-6,7-dihydro-5H,13H-quinazolino 3,2-a 1,4 benzodiazepine-5,13-dione.

Claim 9

A process for the production of a compound according to claim 1 which comprises reacting 2-alkyl-3-aryl-4H-quinazolin-4-one of the formula (II) or an acid-additon salt thereof: ##STR45## in which R 3 and R 4 have the same meaning as defined herein-before in claim 1, formula (I), R 1' and R 5' are the same or different and each represents 0, 1, 2, 3 or 4 substituents which are the same or different and each of which is alkyl, hydroxyl, acyloxy, alkoxy, nitro, dialkylamino, heterocycloalkyl containing at least one nitrogen atom in the ring through which it is bonded, acylamino, acylalkylamino, alkoxycarbonylamino, halogen, trifluoromethyl, cyano, alkoxycarbonyl, dialkylaminocarbonyl, aminosulphonyl, alkylaminosulphonyl, dialkylaminosulphonyl and dialkylaminocarbonylamine each of said alkyl, alkoxy and acyl radicals having 1 to 4 carbon atoms, R 6 is hydrogen, C 1 -C 2 alkyl, benzyl or phenyl and X is a leaving group which can be replaced nucleophillically, with an amine of the following formula (III) or an acid-addition salt thereof: H.sub.2 N--R.sup.2' (III) in which R 2' is hydrogen, alkyl having from 1 to 6 carbon atoms and optionally substituted by phenyl, pyridyl, halogen, alkoxy or dialkylamino, each of the alkyl and alkoxy moieties containing from 1 to 4 carbon atoms, or an alkoxycarbonyl group having from 1 to 4 carbon atoms in the alkoxy moiety and R 1 and/or R 5 is amino, alkylamino, carboxyl, aminocarbonyl, alkylaminocarbonyl or alkylaminocarbonylamino a said corresponding compound of formula I in which R 1 and/or R 5 is nitro or acylamino, acylalkylamino, alkoxycarbonyl, and/or cyano, or amino, respectively is converted thereto, and in the case of a compound of formula I in which R 2 is acyl or alkoxycarbonyl a said corresponding compound of formula I in which R 2 is hydrogen is converted thereto.

Claim 10

A process according to claim 8 in which the reaction is carried out at from 20° to 250° C.

Claim 11

A process according to claim 8 in which the reaction is carried out in the presence of an acid-binding agent.

Claim 12

A process according to claim 8 in which the reaction is carried out in the presence of an inert solvent.

Claim 13

A pharmaceutical composition containing as an active ingredient an amount effective for providing central nervous system action of a compound according to claim 1 in admixture with a solid or liquefied gaseous diluent or in admixture with a solid or liquefied gaseous diluent or in admixture with a liquid diluent other than a solvent of a molecular weight less than 200 except in the presence of a surface-active agent.

Claim 14

A pharmaceutical composition of claim 12 in the form of a sterile or physiologically isotonic aqueous solution.

Claim 15

A composition according to claim 12 containing from 0.5 to 95% by weight of the said active ingredient.

Claim 16

A medicament in dosage unit form comprising an amount effective for providing central nervous system action of a compound of claim 1 and an inert pharmaceutical carrier.

Claim 17

A medicament of claim 15 in the form of tablets, pills, dragees, capsules, ampoules, or suppositories.

Claim 18

A medicament in dosage unit form comprising an amount effective for providing central nervous sytem action of a compound of claim 4 and in inert pharmaceutical carrier.

Claim 19

A method of treating the central nervous system in warm-blooded animals which comprises administering to the said animals an amount effective for providing central nervous system action of an active compound according to claim 1 either alone or in admixture with a diluent or in the form of a medicament.

Claim 20

A method according to claim 18 in which the active compound is administered in an amount of from 0.1 to 500 mg per kg body weight per day.

Claim 21

A method according to claim 18 in which the animals are ruminants.

Claim 22

A method according to claim 18 in which the active compound is administered orally.